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N-acetylglucosaminyltransferase V (GnT-V), an enzyme with a key role in the branching of asparagine-linked
oligosaccharides, is strongly linked to tumor invasion and metastasis of many solid tumors. Here we searched for
correlations between the clinical features of patients with oral squamous cell carcinoma (OSCC) and GnT-V expression
in the tumor, and we studied the feasibility of using GnT-V as a marker for oral cancer prognosis. Samples from
68 patients with OSCC were examined by immunohistochemistry using antibodies against GnT-V. Correlations
between the expression level of GnT-V in the tumor and patient clinical features were statistically analyzed. Positive
GnT-V expression was found in 48 cases (70.6%), and negative GnT-V expression was found in 20 cases (29.4%).
Negative GnT-V expression was associated with mode of invasion by multiple logistic regression analysis (OR:
3.605; P = 0.048). Biological characteristics of tumors and the Ki-67 labeling index were higher in tumors with negative
GnT-V expression than in those with positive GnT-V expression, although the difference was not significant (P = 0.176).
Patients with negative GnT-V expression had significantly shorter survival than those with tumors having positive GnT-V
expression (5-year survival rate, 58.2% and 86.5%, respectively; P = 0.025). Negative GnT-V expression was a significant
unfavorable prognostic factor for OSCC (hazard ratio, 4.246; P = 0.045). The loss of GnT-V expression is a likely indicator
of tumors with high potential of tumor invasion and poor prognosis in OSCC patients.
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Head and neck carcinoma, which includes cancers of
the oral cavity, oropharynx, larynx, and hypopharynx, is
the sixth most common cancer worldwide and has an
incidence of around 600,000 cases per year (Kamangar
et al. 2006). Oral cancer, the largest subset of head and neck
cancer, has become one of the most lethal malignancies
(Chen et al. 2013), of which oral squamous cell carcinoma
(OSCC) is the most frequent histological type (Parkin
et al. 2005). The current management and treatment of* Correspondence: kahoo0903@yahoo.co.jp
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in any medium, provided the original work is pOSCC involves multimodal approaches comprising surgery,
chemotherapy, and radiotherapy (Seiwert and Cohen 2005).
Despite recent advances in early detection, diagnosis,
and treatment, the 5-year survival for patients with OSCC
has remained at 50% for the past 30 years (Forastiere et al.
2003). Because of the high prevalence and mortality rate
of oral cancers, prevention and early intervention are
important strategies for managing the disease.
Glycosylation of cell-surface glycoproteins is widely
accepted to play a key role in various specific biological
interactions. The glycosyltransferase plays a crucial
role on the protein glycosylation. Glycosyltransferase,
located in the Golgi apparatus, includes at least six
N-acetylglucosaminyltransferase (GnT) defined as GnT-I-
VI (Taniguchi et al. 1999). GnT-V, a glycosyltransferase
encoded by the Mgat5 gene that catalyzes the formationopen access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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glycans, is believed to be associated with cancer growth
and metastasis (Taniguchi et al. 1999; Lau and Dennis
2008). Moreover GnT-V protein could results in tumor
angiogenesis, and its mechanism as an inducer of
angiogenesis was different from original function as a
glycosyltransferase (Saito et al. 2002).
Numerous studies have shown that GnT-V is positively
correlated with malignancy in many types of tumor,
including breast, colon, endometrial, and ovarian mucin-
ous tumors (Fernandes et al. 1991; Murata et al. 2000;
Yamamoto et al. 2007; Takahashi et al. 2009). In contrast,
the opposite results have been found for lung, thyroid,
and liver tumors. As such, GnT-V expression and its
functional and prognostic significance in human cancer
remain controversial. The relationship between GnT-V
expression and malignancy has been studied in many
types of tumor, but not in human oral SCC. In vitro
analysis, it was reported that the decrease inβ1, 6GlcNAc
branching on cisplatin-resistant human SCC cell line, so
the GnT-V expression in SCC may be inversely corelated
with prognosis (Nakahara et al. 2003).
In this study, we examined GnT-V expression by im-
munohistochemistry for surgically resected OSCC and
analyzed the correlation with clinical features of OSCC.Figure 1 Representative photomicrographs of immunohistochemical
Negative staining (total absence of GnT-V immunostaining) (A), and pMaterials and methods
Patients and tissue specimens
Tumor specimens were obtained from 68 patients with
OSCC seen at the Department of Oral and Maxillofacial
Surgery, University of Tsukuba Hospital, Ibaraki, Japan
during the period 1994–2004. Patients were followed
for more than 60 months. Tumors were staged accord-
ing to the International Union Against Cancer scheme
(Sobin and Wittekind 1997), and clinical data were
obtained from patient medical records. Specimens
were obtained after patients gave informed consent,
and the study protocol was reviewed and approved by
the Research Ethics Committee of the University of
Tsukuba (H25-43).Immunohistochemistry
For immunostaining of GnT-V, 2-μm thick sections from
patient samples were stained using the Vecta staining
kit according to the manufacturer’s instructions with
anti-GnT-V antibody obtained from Dr. Eiji Miyoshi
(Osaka University, Osaka, Japan). GnT-V expression
levels were classified into two groups according to the
percentage of positively stained cells in the cancerous
area: ≥ 30% (positive) and < 30% (negative) (Takahashistaining with N-acetylglucosaminyltransferase (GnT-V) antibodies
ositive staining (B) (original magnification, ×40 and × 400).
Seto et al. SpringerPlus 2013, 2:657 Page 3 of 6
http://www.springerplus.com/content/2/1/657et al. 2009) (Figure 1). The scoring procedure was carried
out twice by two independent observers who were blinded
to the clinical data.Table 1 Relationship between GnT-V expression and
clinical and clinicopathological characteristics in all
68 patients
GnT-V positive GnT-V negative P
Age
Average 68.88 59.15 0.006
Gender
Male 22 15
Female 26 5 0.028
Alcohol
no 33 8
yes 15 12 0.027
Smoking
no 32 9
yes 16 11 0.096
T-Category
1, 2 30 13
3, 4 18 7 0.845
Clinical Stage
I, II 27 9
III, IV 21 11 0.397
Differentiation
Well 33 9
Moderate, poor 15 11 0.066
Mode of invasion
1 to 3 32 7
4 16 13 0.016
pN
Negative 42 15
Positive 6 5 0.202
Recurrence
Negative 38 15
Positive 10 5 0.178
Metastasis
Negative 38 14
Positive 10 6 0.416
Survival
Alive 43 13
Dead 5 7 0.015
theraphy
Operation 34 11
Chemoradiotheraphy 14 9 0.208Statistical analysis
To simplify the correlation analysis of GnT-V expression
with clinical features, tumors were divided into the T-
category groups T1 + T2 or T3 + T4. Clinical stage was
classified as I + II or III + IV, and differentiation as well-/
moderately or poorly differentiated. Anneroth grade to
denote tumor invasion was assigned as 1–3 or 4. For
univariate analysis, we used the Chi-squared test, Student’s
test, or Welch’s t-test. For multivariate analysis, we used
multiple logistic regression analysis. All analysis was
performed using the statistical software package SPSS.Results
Univariate analysis of GnT-V expression
Positive GnT-V expression was observed in 48 specimens
(70.6%) and negative GnT-V expression in 20 specimens
(29.4%). Table 1 shows the correlation between GnT-V
expression and clinicopathological features. The GnT-V-
negative group included significantly more young patients
(P = 0.006), more males than females (P = 0.028), alcohol
consumption (P = 0.027), more invasive tumors (P = 0.016),
and a higher 5-year survival rate (P = 0.015). No significant
difference in GnT-V expression was observed with respect
to other factors, including, smoking, T-category, clinical
stage, cellular differentiation, pN positive or negative, local
recurrence, lymph node metastasis, and treatment type.
No difference was observed between GnT-V expression
and p53 expression. Ki-67 labeling index values were
higher in tumors with negative GnT-V expression than
in those with positive GnT-V expression, but not sig-
nificantly (P = 0.176) (Table 2).Multivariate analysis of GnT-V expression
The predictor variables in the 68 patients were used in a
logistic regression model with GnT-V expression as the
dependent variable. The logistic model was constructed
using clinical variables, including age, gender, alcohol
consumption, smoking, stage, differentiation, and Mode
of invasion. Adjusted odds ratios (OR) and P values are
shown in Table 3. Negative staining for GnT-V (OR= 3.605
and P = 0.048) was significantly associated with invasion
but not with the other variables.Table 2 The relationship between GnT-V expression and
p53, ki 67 expression
GnT-V positive GnT-V negative P
p53
Negative 33 16
Positive 15 4 0.346
Ki67 mib index (Mean ± SD)
14.0 ± 1.9 19.8 ± 4.6 0.176
Table 3 Multiple logistic regression analysis for the
correlation between GnT-V expression and clinical
characteristics
Characteristics Odds ratio P
Age 1.048 0.052
Gender (male/female) 0.502 0.415
Alcohol (no alcohol/alcoho drinker) 1.750 0.464
Smoking (non smoker/smoker) 1.378 0.639
Stage (I + II/III + IV) 1.135 0.866
Differentiation (well/moderate + poor) 1.391 0.597
Mode of invasion (1-3/4) 3.605 0.048
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We next analyzed the relationship between GnT-V expres-
sion and patient survival and the importance of GnT-V
as a prognostic factor. Kaplan-Meier survival curves clearly
demonstrated that patients with negative GnT-V expres-
sion had significantly shorter survival than patients
with positive GnT-V expression (5-year survival rate,
58.2% and 86.5%, respectively; P = 0.025; Figure 2). Cox
proportional-hazard analysis was performed to compare
the impact of GnT-V expression on survival with currently
used clinicopathological prognostic factors such as age,
gender, alcohol consumption, smoking consumption, stage,
differentiation, and GnT-V expression. Negative GnT-V
expression was the only significant unfavorable prognostic
factor in our analysis (hazard ratio, 4.246; P = 0.045)
(Table 4).
Discussion
Glycosylation is one of the most common posttranslational
protein modifications, and nearly half of all known proteins
in eukaryotes are glycosylated (Saxon and Bertozzi 2001).
Cell surface glycosylation not only regulates the stability
and activity of structural proteins and receptors on theFigure 2 Kaplan Meier disease-free survival of GnT-V expression in al
expression and negative GnT-V expression were 86.5 % and 58.2%, respectcell membrane, but also participates in the maintenance of
cell morphology and cell-cell interactions (Hirai-Fujita
et al. 2008; Krishnan et al. 2005; Rak et al. 1991). Changes
in glycans are associated with many physiological and
pathological events, including cell adhesion, migration,
and invasion (Dennis et al. 1987).
The present report shows that GnT-V expression in
OSCC is associated with age (P = 0.006), gender (P =
0.028), alcohol consumption (P = 0.027), mode of invasion
(P = 0.016), and 5-year survival (P = 0.015). Although our
results revealed that there were no significant differences
between GnT-V expression and T or Clinical stages, it was
reported that GnT-V expression is upregulated in the early
stages of almost all cancers (Miyoshi et al. 2012). However
Multiple logistic regression analysis to determine the
correlation between GnT-V expression and clinical and
clinicopathological characteristics showed that the cases of
negative GnT-V expression tended to be more invasive as
determined by Anneroth grade.
Kaplan-Meier survival curves clearly demonstrated that
patients with negative GnT-V expression had significantly
shorter survival than patients with positive GnT-V
expression (5-year survival rate, 58.2% and 86.5%, respect-
ively; P = 0.025; Figure 2). Historogy was significantly
correlated with GnT-V expression and low GnT-V expres-
sion was more frequently found in squamous cell car-
cinomas than non-squamous cell carcinomas (Akita
2004). Our data strongly suggested that the relationship
between GnT-V expression and the prognosis depends
on the histrogical type, as well as the original organ of
the cancer. When considering survival rate, the type of
treatment (surgery or chemoradiotherapy) was taken
into account, but we found no significant correlation
between GnT-V expression and treatment type. More-
over, in patients with negative GnT-V expression that
correlated with survival rate, we found no significantl patients. The 5-year disease-free survival (DFS) rates of positive GnT-V
ively (P = 0.025).
Table 4 Cox proportional hazards model analysis of prognostic factors in patients
Characteristics Hazard ratio 95% CI P
Age 1.060 0.992-1.132 0.083
Gender (male/female) 0.488 0.093-2.565 0.397
Alcohol (no alcohol/alcoho drinkerl) 1.436 0.333-6.199 0.627
Smoking (non smoker/amoker) 1.814 0.444-7.408 0.407
Clinical stage (I, II / III, IV) 2.428 0.541-10.896 0.247
Differentiation (well/moderate + poor) 1.016 0.286-3.612 0.980
GnT-V expression 4.246 1.0320-17.586 0.045
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rence or node metastasis. This suggests that negative
GnT-V expression reduces the efficacy of chemoradio-
therapy as a second treatment. This implies that OSCC
patients with negative GnT-V expression are more
likely to have poor prognosis.
The relationship between cisplatin-resistance and α5β1
integrin with β1-6GlcNAc branching has been reported
in an established cisplatin-resistant head and neck
carcinoma cell line, but reasons for the relationship
are unclear (Nakahara et al. 2003). Down-regulation of
GnT-V enhances nasopharyngeal carcinoma cell radio-
sensitivity both in vitro and in vivo, and is linked to
the G2-M cell cycle arrest and the reduction of the BcL-2/
Bax ratio (Zhuo et al. 2012). Conversely, a correlation
was found between the high expression levels of GnT-V
in neuroblastoma patients with a favorable prognosis,
suggesting that GnT-V can cause neuroblastomas to
regress by increasing their susceptibility to apoptosis
(Inamori et al. 2006).
Low expression of GnT-V may contribute to altered
biological properties of bladder cancer as well as non-
small cell lung cancer and hepatocellular carcinoma by
decreasing the synthesis of β1-6 branching oligosaccharides
of certain target glycoproteins, resulting in shorter survival
in patients having tumors with low GnT-V expression
compared with patients having tumors with high GnT-V
expression (Akita 2004; Ishimura et al. 2006; Ito et al.
2001). The importance of this oligosaccharide structure
as a precursor to malignancy differs between organs,
and the target substrate of GnT-V might differ between
oral cancer and other carcinomas. However, from a clinical
background, there is not a significant difference with
the tumor differentiation with GnT-V expression in
OSCC as observed in the other cancer that prognosis
was inversely correlated with GnT-V expression. In
addition, since expression of GnT-V expression is low
in young people, histologic pattern might be different
in GnT-V positive and negative cases.
Taken together, immunohistochemistry of OSCC speci-
mens can provide information that could help physicians
make appropriate decisions for the treatment of cancerpatients. For example, if GnT-V expression is absent,
the tumor is more likely to have poor prognosis, and
radical treatment in such a case would be a better
choice. However the potential oncogenic role and under-
ling mechanisms of GnT-V in OSCC have not been
investigated. Clealy, further studies are needed to elucidate
the mechanisms of GnT-V promoting the development
and metastasis of OSCC in detail.
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